Cholecystokinin Peptidomimetics as Selective CCK-B Antagonists: Design, Synthesis, and in Vitro and in Vivo Biochemical Properties

Journal of Medicinal Chemistry

Volumn 36, Issue 20, 1993, Pages 2868-2877

  Blommaert, Armand G S ^a   Weng, Jian Hui ^a   Dorville, Agnès ^a   McCort, Isabelle ^a   Ducos, Bertrand ^a   Durieux, Christiane ^a   Roques, Bernard P ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; N [N [(2 ADAMANTYLOXY)CARBONYL] DEXTRO ALPHA METHYLTRYPTOPHANYL] N [2 (4 CHLOROPHENYL)ETHYL]GLYCINE; PBC 264; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; DRUG DESIGN; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GUINEA PIG; LIPOPHILICITY; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PANIC; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADAMANTANE; ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; CELL MEMBRANE; CHOLECYSTOKININ; COMPARATIVE STUDY; DIPEPTIDES; GUINEA PIGS; MICE; MOLECULAR STRUCTURE; RATS; RECEPTORS, CHOLECYSTOKININ; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; THERMODYNAMICS;

EID: 0027489992     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00072a005     Document Type: Article

References (49)

1. Innis, R. B.; Snyder, S. H. Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 6917–6921.
2. Moran, T. H.; Robinson, P. H.; Goldrich, M. S.; McHugh, P. R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 1985, 362, 175–179.
3. Wank, S. A.; Pisegna, J. R.; De Weerth, A. Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 8691–8695.
4. Pisegna, J. R.; De Weerth, A.; Huppi, K.; Wank, S. A. Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosal localization. Biochem. Biophys. Res. Commun. 1992, 189, 296–303.
5. Kopin, A. S.; Lee, Y. M.; McBride, E. W.; Miller, L. J.; Lu, M.; Lin, H. Y.; Kolakowski, L. F.; Beinborn, M. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3605–3609.
6. 3H]SNF 8702. Mol. Pharmacol. 1992, 41, 1089–1095.
7. Singh, L.; Lewis, A. S.; Field, M. J.; Hughes, J.; Woodruff, G. N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1130–1133.
8. Itoh, S.; Lal, H. Influences of cholecystokinin and analogues on memory processes. Drug Dev. Res. 1990, 21, 257–276.
9. Daugé, V.; Derrien, M.; Blanchard, J. C.; Roques, B. P. The selective CCK-B agonist, BC 264 injected in the anterolateral part of the nucleus accumbens, reduces the spontaneous alternation beviour of rats. Neuropharmacology 1992, 31, 67–75.
10. Faris, P. L.; Komisaruk, B. R.; Watkins, L. R.; Mayer, D. J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219, 310–312.
11. Noble, F.; Derrien, M.; Roques, B. P. Modulation of opioid analgesia by CCK: evidence of regulatory mechanisms between CCK and enkephalin systems in the supraspinal control of pain. Br. J. Pharmacol., in press.
12. Schalling, M.; Friberg, K.; Seroogy, K.; Riederer, P.; Schiffman, S. N.; Mailleux, P.; Vanderhaeghen, J.-J.; Kuga, S.; Goldstein, M.; Kitahama, K.; Luppi, P. H.; Jouvet, M.; Hökfelt, T. Analysis of expression of cholecystokinin in the ventral mesencepalon of several species and in humans with schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 8427–8431.
13. Wang, R. Y.; White, F. J.; Voigt, M. M. Cholecystokinin, dopamine and schizophrenia. Trends Pharmacol. Sci. 1984, 5, 436–438.
14. B antagonist, blocks CCK-4-panic attacks in patients with panic disorder. Clin. Neuropharm. 1992, 15, Suppl. 1, 9.
15. Bradwejn, J.; Koszycki, D.; Shriqui, C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch. Gen. Psychiatry 1991, 48, 603–610.
16. Daugé, V.; Böhme, G. A.; Crawley, J. N.; Durieux, C.; Stutzmann, J. M.; Féger, J.; Blanchard, J. C.; Roques, B. P. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCK-B receptors by using a new highly potent CCK analog, BC 264. Synapse 1992, 6, 73–80.
17. 4 binding sites in mouse and rat brain. Neuropeptides 1988, 12, 141–148.
18. Dourish, C. T.; O'Neill, M. F.; Coughlan, J.; Kitchener, S. J.; Hawley, D.; Iversen, S. D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 1990, 176, 35–44.
19. Derrien, M.; Maldonado, R.; Durieux, C.; Noble, F.; Branchereau, P.; Dauge, V.; Roques, B. P. Electrophysiological and behavioral studies of CCK in analgesia and anxiety using selective CCK-A and CCK-B compounds. Second Kelvin Conference, in press.
20. Maldonado, R.; Derrien, M.; Noble, F.; Roques, B. P. Association of the peptidase inhibitor RB101 and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport, in press.
21. Bock, M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L.; Veber, D. F.; Anderson, P. S.; Freidinger, R. M. Benzodiazepine Gastrin and Brain Cholecystokinin Receptor Ligands: L-365,260. J. Med. Chem. 1989, 32, 13–16.
22. Horwell, D. C.; Hughes, J.; Hunter, J. C.; Pritchard, M. C.; Richardson, R. S.; Roberts, E.; Woodruff, G. N. Rationally Designed “Dipeptoid” Analogues of CCK. α-Methyltryptophan Derivatives as highly Selective and Orally Active Gastrin and CCK-B Antagonists with Potent Anxiolytic Properties. J. Med. Chem. 1991, 34, 404–414.
23. Böhme, A.; Bertrand, P.; Pendley, C.; Doble, A.; Guyon, C.; Martin, G.; Stutzmann, J. M.; Dubroeucq, M. C.; Blanchard, J. C. RP 69758, novel cholecystokinin B type and gastrin antagonist. Nanym-Schmiedeberg's Arch. Pharmacol. 1992, 345, R116.
24. Rasmussen, K.; Czachura, J. F.; Stockton, M. E.; Howbert, J. J. Electrophysiological effects of Diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 1992, 264, 480–488.
25. Yu, M. J.; Thrasher, K. J.; McCowan, J. R.; Mason, N. R.; Deeter, J. B.; Mendelsohn, L. G. Quinazolinone cholecystokinin-B receptor ligands. J. Med. Chem. 1991, 34, 1505–1508.
26. Dethloff, L. A.; De La Iglesia, F. A. Cholecystokinin antagonists-A toxicologic perspective. Drug Met. Rev. 1992, 24, 267–293.
27. Chen, I. W.; Dorley, J. M.; Ramjit, H. G.; Pitzenberger, S. M.; Lin, J. H. Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals. Drug Metab. Dispos. 1992, 20, 390–395.
28. 2 and derivatives: A new family of CCK antagonists. J. Med. Chem. 1990, 33, 3199–3204.
29. 4 derivatives. J. Med. Chem. 1993, 36, 166–172.
30. Nystrom, R. F. Reduction of Organic Compounds by Mixed Hydrides. I. Nitriles. J. Am. Chem. Soc. 1955, 77, 2544–2545.
31. Kier, L. D.; Dhawan, D. Synthesis of Sydnones as Potential Therapeutic Agents. J. Pharm. Sci. 1962, 51, 1058–1061.
32. Anantharamaiah, G. M.; Roeske, R. W. Resolution of α-methyl amino esters by chymotrypsin. Tetrahedron Lett. 1982, 23, 3335–3336.
33. O'Donnell, M. J.; LeClef, B.; Rusterholz, D. B.; Ghosez, L.; Antoine, J. P.; Navarro, M. α-Methyl amino acids by catalytic phase-transfer alkylations. Tetrahedron Lett. 1982, 41, 4259–4262.
34. Stork, G.; Leons, A. Y. W.; Touzain, A. M. Alkylation and Michael Additions of Glycine Ethylester. Use in α-Amino Acid Synthesis and as Acyl Carbanion Equivalent. J. Org. Chem. 1976, 41, 3491–3493.
35. Horwell, D. C.; Birchmore, B.; Boden, P. R.; Higginbottom, M.; Ping Ho, Y.; Hughes, J.; Hunter, J. C.; Richardson, R. S. α-Methyltryptophanylphenylalanines and their arylethylamine “dipeptoid” analogues of the tetrapeptide cholecystokinin (30–33). Eur. J. Med. Chem. 1990, 25, 53–60.
36. Charpentier, B.; Durieux, C.; Pélaprat, D.; Dor, A.; Reibaud, M.; Blanchard, J. C.; Roques, B. P. Enzyme-resistant CCK analogues with high affinities for central receptors. Peptides 1988, 9, 835–841.
37. Hittingbottom, M.; Kneen, C.; Ratcliffe G. S. Rationally designed “dipeptoid” analoques of CCK. A Free-Wilson/Fujita-Ban analysis of some α-methyltryptophan derivatives as CCK-B antagonists. J. Med. Chem. 1992, 35, 1572–1577.
38. Drysdale, M. J.; Pritchard, M. C.; Horwell, D. C. Rationally Designed Dipeptoid Analogues of CCK. Acid Mimics of the Potent and Selective Non-peptide CCK-B Receptor Antagonist CI988. J. Med. Chem. 1992, 35, 2573–2581.
39. Magous, R.; Martinez, J.; Lignon, M. F.; Bali, J. P. The role of the Asp-32 residue of cholecystokinin in gastric acid secretion and gastrin receptor recognition. Regul. Pept. 1983, 6, 327–332.
40. 30 modified analogs of Ac-CCK-7. Int. J. Peptide Protein Res. 1992, 337–347.
41. Boden, P. R.; Higginbottom, M.; Hill, D. R.; Horwell, D. C.; Hughes, J.; Rees, D. C.; Roberts, E.; Singh, L.; Suman-Chauhan, N.; Woodruff, G. N. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and mixed CCK-A/CCK-B antagonists. J. Med. Chem. 1993, 36, 552–565.
42. Topliss, J. G. Utilization of Operational Schemes for Analog Synthesis in Drug Design. J. Med. Chem. 1972, 15, 1006–1011.
43. Morley, J. E.; Levine, A. S.; Bartness, T. J.; Nizielsky, S. E.; Shaw, M. J.; Hughes, J. J. Species differences in the response to cholecystokinin. Ann. NY Acad. Sci. 1985, 488, 413–416.
44. 8H]pBC 264, first highly potent and very selective radioligand for CCK-B receptors. Eur. J. Pharmacol. 1989, 168, 269–270.
45. 3H]pBC 264. Eur. J. Pharmacol. 1991, 209, 185–193.
46. Hargreaves, R. J.; Lin, J. H. Blood-brain transfer of the CCK antagonists L-365,260 and devazepide. In Multiple Cholecystokinin Receptors in the CNS; Dourish, C. T., Cooper, S. J., Iversen, S. D., Iversen, L., Eds.; Oxford University Press: New York, 1992; pp 107–114.
47. 26–33-related analogues in position 31. J. Med. Chem. 1988, 31, 966–970.
48. 1H-NMR spectroscopy, fluorescence-transfer measurements and calculations. Biochemistry 1986, 25, 3778–3787.
49. Pincus, M. R.; Murphy, R. B.; Carty, R. P.; Chen, J.; Shah, D.; Scheroga, H. A. Conformational analysis of possible biologically active (receptor-bound) conformations of peptides derived from cholecystokinin, cerulein and little gastrin and the opiate peptide, Met-Enkephalin. Peptides 1988, 9, 145–152.